The goal of this project is to employ novel therapies in patients who are at risk for or who have early ARDS in order to reduce the significant attributable mortality and to improve both short term and long term morbidities (1,2). As a participant in the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network, our specific aims are: 1. The creation of a two site multi-disciplinary network for recruitment into PETAL studies. Principal Investigators and Co-investigators from the Divisions of Pulmonary and Critical Care Medicine, Acute Care Surgery, and the Emergency Department Intensive Care Unit (ED-ICU) at the University of Michigan will collaborate to insure early identification and robust recruitment o study subjects. Additionally, investigators from the Emergency Department and the Division of Pulmonary and Critical Care Medicine of Henry Ford Health System, our second site in this network, have joined to create a rich environment in which to recruit patients for PETAL studies. This environment is strengthened by the inclusion of a fully integrated ED-ICU, providing a unique continuum of care for critically ill patients at these institutions, permitting early recruitment and intervention in these patients. 2. The annual recruitment of at least 40 high quality enrollees into PETAL protocols through the continuation and initiation of multiple overlapping recruitment strategies, including a novel alert mechanism through the electronic medical record, calculation of lung injury prevention scores, targeted capture of select at risk populations and traditional coordinator screening. 3. Prevention of ARDS: To determine the effect of GM-CSF administration on relevant clinical outcomes in patients with severe sepsis who are at risk for ARDS. The primary outcome measures are 28- and 90-day mortality. Major secondary end-points include the development/progression of ARDS and other organ failures, resolution of sepsis, duration of ICU and hospital stay, and long term functional recovery. Biological outcomes include monocyte innate responses and systemic inflammatory responses. 4. Early intervention in ARDS: To determine the effect of azithromycin administration on relevant clinical outcomes in patients with early onset ARDS. The primary outcome measures are 28- and 90-day mortality. Major secondary end-points include ventilator-free days, organ failure free days, infectious complications, duration of ICU and hospital stay, and long term functional recovery. An important biological outcome to be assessed is the influence of azithromycin therapy on temporal changes in the lung microbiome. These highly novel studies are to be led by a Co-Investigator with outstanding expertise in this arena.

Public Health Relevance

The acute respiratory distress syndrome (ARDS) is a frequent event in critically ill patients and is a cause of significant mortality and morbidity in the Unite States. We have previously demonstrated why GM-CSF and azithromycin are potentially useful interventions in patients either at risk for or having ARDS. The studies proposed in this application may result in improved outcomes in ARDS patients which could include a lower mortality or less long term disability.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-S (F1))
Program Officer
Harabin, Andrea L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Internal Medicine/Medicine
Schools of Medicine
Ann Arbor
United States
Zip Code
Standiford, Theodore J; Ward, Peter A (2016) Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Transl Res 167:183-91
Benthin, Cody; Pannu, Sonal; Khan, Akram et al. (2016) The Nature and Variability of Automated Practice Alerts Derived from Electronic Health Records in a U.S. Nationwide Critical Care Research Network. Ann Am Thorac Soc 13:1784-1788
Brown, Samuel M; Grissom, Colin K; Moss, Marc et al. (2016) Nonlinear Imputation of Pao2/Fio2 From Spo2/Fio2 Among Patients With Acute Respiratory Distress Syndrome. Chest 150:307-13
Dickson, Robert P; Singer, Benjamin H; Newstead, Michael W et al. (2016) Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol 1:16113
Sevransky, Jonathan E; Checkley, William; Herrera, Phabiola et al. (2015) Protocols and Hospital Mortality in Critically Ill Patients: The United States Critical Illness and Injury Trials Group Critical Illness Outcomes Study. Crit Care Med 43:2076-84